

What is claimed is:

1. A liquid composition comprising an antibody against human interleukin-4 receptor alpha, wherein the liquid composition comprises the antibody at a concentration of ~~50-200~~100-165 mg/ml; and a buffer, a protective agent and a surfactant which serve as excipients, and wherein the antibody comprises a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 4, a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 8, a light chain constant region comprising the amino acid sequence as set forth in SEQ ID NO: 9 and a heavy chain constant region comprising the amino acid sequence as set forth in SEQ ID NO: 10; and the liquid composition has a pH of ~~5.4-6.4~~ 6.2 ± 0.2 ; and wherein the buffer is histidine hydrochloride buffer at a concentration of 5-10 mmol/L, the protective agent is a combination of 60-150 mmol/L trehalose and 80-120 mmol/L sodium chloride, and the surfactant is 0.01%-0.2% Tween 80.

2. The liquid composition according to Claim 1, wherein in the liquid composition, ~~the antibody comprises a light chain variable region and a heavy chain variable region, and wherein the light chain variable region comprises CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, and CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, and the heavy variable region comprises CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7;~~

~~preferably, the antibody comprises a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 4, and a heavy variable region comprising the amino acid sequence as set forth in SEQ ID NO: 8;~~

~~preferably, the antibody is present at a concentration of 100-200 mg/ml, more preferably 130-165 mg/ml.~~

3. The liquid composition according to Claim 1, wherein in the liquid composition, the antibody is present at a concentration of, and further preferably 150 ± 5 mg/ml.

~~3. The liquid composition according to Claim 1 or 2, wherein the buffer is one or more selected from the group consisting of an acetate buffer, a phosphate buffer and an amino acid buffer, and the buffer is present at a concentration of 5-50 mmol/L; preferably, the buffer is an amino acid buffer at a concentration of 5-50 mmol/L.~~

~~4. The liquid composition according to Claim 3₁, wherein the acetate buffer is sodium acetate buffer, the phosphate buffer is sodium dihydrogen phosphate buffer, or the amino acid buffer is histidine hydrochloride buffer;
preferably, the buffer is present at a concentration of 5-20 mmol/L;
preferably, the buffer is histidine hydrochloride buffer at a concentration of 5-20 mmol/L,
more preferably histidine hydrochloride buffer at a concentration of 10 mmol/L.~~

~~5. The liquid composition according to any one of Claims 1 to 4, wherein the protective agent is one or more selected from the group consisting of a sugar, an alcohol, an amino acid and a chloride salt, and the protective agent is present at a concentration of 40-220 mmol/L.~~

~~6₅. The liquid composition according to Claim 5₁, wherein the protective agent is one or more selected from the group consisting of a sugar, an alcohol and an amino acid, and the protective agent is present at a concentration of 40-220 mmol/L, and/or the protective agent is a chloride salt, and the protective agent is present at a concentration of 40-150 mmol/L;
preferably, the sugar is trehalose and/or sucrose at a concentration of 40-150 mmol/L, more preferably 60-150 mmol/L; the alcohol is mannitol at a concentration of 40-220 mmol/L, more preferably 110-150 mmol/L; the amino acid is one or more selected from the group consisting of proline, arginine hydrochloride and glycine at a concentration of 40-220 mmol/L, more preferably 120-220 mmol/L; or the chloride salt is sodium chloride at a concentration of 40-150 mmol/L, more preferably 80-120 mmol/L;
preferably, in the liquid composition, the protective agent is a combination of trehalose and sodium chloride; more preferably, the protective agent is a combination of 40-150~~

mmol/L trehalose and 40-150 mmol/L sodium chloride; further preferably, the protective agent in the liquid composition is a combination of 60-150 mmol/L trehalose and 80-120 mmol/L sodium chloride, more preferably a combination of 60 mmol/L trehalose and 100 mmol/L sodium chloride.

~~76.~~ The liquid composition according to ~~any one of Claims 1 to 6~~, wherein the surfactant is a non-ionic polymer such as is one or more selected from the group consisting of Tween 80, Tween 20, Poloxamer and polyethylene glycol, and the surfactant is present at a concentration of 0.01%-0.2%;
preferably, the surfactant is 0.01-0.03% Tween 80.

7. The liquid composition according to Claim 1, wherein the surfactant is more preferably 0.02% Tween 80.

8. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition is a formulation for injection.

9. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition is a formulation, and preferably for subcutaneous or intravenous injection.

10. The liquid composition according to any one of Claims 1 to 7, wherein the liquid composition preferably, the liquid composition comprises:

130-165 mg/ml, preferably 150±5 mg/ml of the antibody;

10 mmol/L histidine hydrochloride;

60 mmol/L trehalose;

100 mmol/L sodium chloride;

0.02% Tween 80; and

the liquid composition has a pH of 6.2 ± 0.2 , preferably 6.2 ± 0.05 .

11. The liquid composition according to Claim 10, wherein in the liquid composition, the antibody is present at a concentration of 150±5 mg/ml.

12. The liquid composition according to Claim 11, wherein the liquid composition has a pH of 6.2±0.05.

13. Use of the liquid composition according to any one of Claims 1 to 12 for manufacturing a medicament for the treatment of inflammation or allergic disease;

14. The use according to Claim 13preferably, wherein the inflammation or allergic disease includes autoimmune disease.

15. The use according to Claim 13, wherein the inflammation or allergic disease issuch as allergic dermatitis, asthma, eosinophilic esophagitis, eczema, allergic rhinitis, nasal polyp, or rheumatoid arthritis, and the like.

16. A container or a kit comprising the container, wherein the container comprises the liquid composition according to any one of Claims 1 to 15.

17. A kit comprising the container according to Claim 16.

~~11. A method of preventing, treating or ameliorating inflammation or allergic disease, wherein the method includes administering to a subject in need thereof the liquid composition according to any one of Claims 1 to 8;~~

~~preferably, the subject is a mammal, more preferably, a human;~~

~~preferably, the inflammation or allergic disease includes autoimmune disease, such as allergic dermatitis, asthma, eosinophilic esophagitis, eczema, allergic rhinitis, nasal polyp, rheumatoid arthritis, and the like;~~

~~preferably, the liquid composition is administrated to the subject by injection, for example by subcutaneous injection or intravenous injection.~~